Literature DB >> 18701714

The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo.

Matthias Lechmann1, Naomi Shuman, Andrew Wakeham, Tak W Mak.   

Abstract

CD83 is the major surface marker identifying mature dendritic cells (DCs). In this study, we report the generation of reporter mice expressing EGFP under the control of the CD83 promoter. We have used these mice to characterize CD83 expression by various immune system cell types both in vivo and ex vivo and under steady-state conditions and in response to stimulation with a Toll-like receptor (TLR) ligand. With those mice we could prove in vivo that the CD83 promoter is highly active in all DCs and B cells in lymphoid organs. Interestingly, this promoter activity in B cells mainly depended on the stage of development, is up-regulated in the late pre-B cell stage, and was maintained on a high level in all peripheral B cells. We also confirmed that CD83 in those cells is mainly intracellular but is up-regulated after TLR stimulation. Otherwise, CD83 promoter activity in T cells seemed to depend on stimulation and could be found mainly in CD4(+)CD25(+) and CD8(+)CD25(+) T cells and in CD4(+) and CD8(+) memory cells. In addition, we identified the murine homologues of the human CD83 splice variants. In contrast to those in human, those extremely rare short transcripts were never found without the expression of the highly dominant full-length form. So, the murine CD83 surface expression is mainly regulated posttranslationally in vivo. Our CD83 reporter mice represent a useful mouse model for monitoring the activation status and migration of DCs and lymphocytes under various conditions, and our results provide much needed clarification of the true nature of CD83 promoter activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18701714      PMCID: PMC2515619          DOI: 10.1073/pnas.0806335105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Transcription factor NF-kappaB regulates inducible CD83 gene expression in activated T lymphocytes.

Authors:  T A McKinsey; Z Chu; T F Tedder; D W Ballard
Journal:  Mol Immunol       Date:  2000 Aug-Sep       Impact factor: 4.407

Review 2.  Regulation of T cell immunity by dendritic cells.

Authors:  A Lanzavecchia; F Sallusto
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

3.  A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera.

Authors:  B D Hock; M Kato; J L McKenzie; D N Hart
Journal:  Int Immunol       Date:  2001-07       Impact factor: 4.823

4.  Cutting edge: CD83 regulates the development of cellular immunity.

Authors:  Nathalie Scholler; Martha Hayden-Ledbetter; Amber Dahlin; Ingegerd Hellström; Karl Erik Hellström; Jeffrey A Ledbetter
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

5.  CD83 expression influences CD4+ T cell development in the thymus.

Authors:  Yoko Fujimoto; LiLi Tu; Ann S Miller; Cheryl Bock; Manabu Fujimoto; Carolyn Doyle; Douglas A Steeber; Thomas F Tedder
Journal:  Cell       Date:  2002-03-22       Impact factor: 41.582

Review 6.  Antigen decoding by T lymphocytes: from synapses to fate determination.

Authors:  A Lanzavecchia; F Sallusto
Journal:  Nat Immunol       Date:  2001-06       Impact factor: 25.606

7.  Cloning, recombinant expression and biochemical characterization of the murine CD83 molecule which is specifically upregulated during dendritic cell maturation.

Authors:  S Berchtold; P Mühl-Zürbes; C Heufler; P Winklehner; G Schuler; A Steinkasserer
Journal:  FEBS Lett       Date:  1999-11-19       Impact factor: 4.124

8.  Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies.

Authors:  Matthias Lechmann; Elisabeth Kremmer; Heinrich Sticht; Alexander Steinkasserer
Journal:  Protein Expr Purif       Date:  2002-04       Impact factor: 1.650

9.  A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts.

Authors:  Jun-Fa Xu; Bao-Jun Huang; Hui Yin; Ping Xiong; Wei Feng; Yong Xu; Min Fang; Fang Zheng; Cong-Yi Wang; Fei-Li Gong
Journal:  Transpl Int       Date:  2007-03       Impact factor: 3.782

10.  The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells.

Authors:  M Lechmann; D J Krooshoop; D Dudziak; E Kremmer; C Kuhnt; C G Figdor; G Schuler; A Steinkasserer
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  18 in total

Review 1.  Trafficking of immune cells in the central nervous system.

Authors:  Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

2.  C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity.

Authors:  Jason Dunkelberger; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Immunol       Date:  2012-03-19       Impact factor: 5.422

3.  CD83 expression is essential for Treg cell differentiation and stability.

Authors:  Marina Doebbeler; Christina Koenig; Lena Krzyzak; Christine Seitz; Andreas Wild; Thomas Ulas; Kevin Baßler; Dmitry Kopelyanskiy; Alina Butterhof; Christine Kuhnt; Simon Kreiser; Lena Stich; Elisabeth Zinser; Ilka Knippertz; Stefan Wirtz; Christin Riegel; Petra Hoffmann; Matthias Edinger; Lars Nitschke; Thomas Winkler; Joachim L Schultze; Alexander Steinkasserer; Matthias Lechmann
Journal:  JCI Insight       Date:  2018-06-07

4.  Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Authors:  T A Seldon; R Pryor; A Palkova; M L Jones; N D Verma; M Findova; K Braet; Y Sheng; Y Fan; E Y Zhou; J D Marks; T Munro; S M Mahler; R T Barnard; P D Fromm; P A Silveira; Z Elgundi; X Ju; G J Clark; K F Bradstock; D J Munster; D N J Hart
Journal:  Leukemia       Date:  2015-08-19       Impact factor: 11.528

5.  Soluble CD83 ameliorates experimental colitis in mice.

Authors:  J Eckhardt; S Kreiser; M Döbbeler; C Nicolette; M A DeBenedette; I Y Tcherepanova; C Ostalecki; A J Pommer; C Becker; C Günther; E Zinser; T W Mak; A Steinkasserer; M Lechmann
Journal:  Mucosal Immunol       Date:  2014-01-15       Impact factor: 7.313

6.  Functional identification of dendritic cells in the teleost model, rainbow trout (Oncorhynchus mykiss).

Authors:  Elizabeth Bassity; Theodore G Clark
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

7.  Continuous expression of CD83 on activated human CD4⁺ T cells is correlated with their differentiation into induced regulatory T cells.

Authors:  Liwen Chen; Shihe Guan; Qiang Zhou; Shouqin Sheng; Fei Zhong; Qin Wang
Journal:  Mol Med Rep       Date:  2015-05-18       Impact factor: 2.952

8.  Targeting CD83 for the treatment of graft-versus-host disease.

Authors:  Xiongfei Wang; Ming Q Wei; Xiaosong Liu
Journal:  Exp Ther Med       Date:  2013-04-02       Impact factor: 2.447

9.  Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.

Authors:  Bishwas Shrestha; Kelly Walton; Jordan Reff; Elizabeth M Sagatys; Nhan Tu; Justin Boucher; Gongbo Li; Tayyebb Ghafoor; Martin Felices; Jeffrey S Miller; Joseph Pidala; Bruce R Blazar; Claudio Anasetti; Brian C Betts; Marco L Davila
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

10.  microRNA-181a represses ox-LDL-stimulated inflammatory response in dendritic cell by targeting c-Fos.

Authors:  Chaoneng Wu; Yunguo Gong; Jie Yuan; Wenbin Zhang; Gang Zhao; Hua Li; Aijun Sun; Yunzeng Zou; Junbo Ge
Journal:  J Lipid Res       Date:  2012-09-05       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.